vs
Side-by-side financial comparison of Dolby Laboratories, Inc. (DLB) and Bio-Techne (TECH). Click either name above to swap in a different company.
Dolby Laboratories, Inc. is the larger business by last-quarter revenue ($395.6M vs $295.9M, roughly 1.3× Bio-Techne). Dolby Laboratories, Inc. runs the higher net margin — 24.0% vs 12.8%, a 11.1% gap on every dollar of revenue. On growth, Dolby Laboratories, Inc. posted the faster year-over-year revenue change (7.1% vs -6.4%). Over the past eight quarters, Dolby Laboratories, Inc.'s revenue compounded faster (13.9% CAGR vs 4.2%).
Dolby Laboratories, Inc. is an American technology corporation specializing in audio noise reduction, audio encoding/compression, spatial audio, and high-dynamic-range television (HDR) imaging. Dolby licenses its technologies to consumer electronics manufacturers.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
DLB vs TECH — Head-to-Head
Income Statement — Q3 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $395.6M | $295.9M |
| Net Profit | $94.9M | $38.0M |
| Gross Margin | 88.7% | 64.6% |
| Operating Margin | 28.5% | 18.4% |
| Net Margin | 24.0% | 12.8% |
| Revenue YoY | 7.1% | -6.4% |
| Net Profit YoY | 3.4% | 68.3% |
| EPS (diluted) | $0.99 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | $395.6M | — | ||
| Q1 26 | $346.7M | — | ||
| Q4 25 | $346.7M | $295.9M | ||
| Q3 25 | $307.0M | — | ||
| Q2 25 | $315.5M | $317.0M | ||
| Q1 25 | $369.6M | $316.2M | ||
| Q4 24 | $357.0M | $297.0M | ||
| Q3 24 | $304.8M | $289.5M |
| Q2 26 | $94.9M | — | ||
| Q1 26 | $53.3M | — | ||
| Q4 25 | $53.3M | $38.0M | ||
| Q3 25 | $49.3M | — | ||
| Q2 25 | $46.1M | $-17.7M | ||
| Q1 25 | $91.8M | $22.6M | ||
| Q4 24 | $67.8M | $34.9M | ||
| Q3 24 | $58.6M | $33.6M |
| Q2 26 | 88.7% | — | ||
| Q1 26 | 87.5% | — | ||
| Q4 25 | 87.5% | 64.6% | ||
| Q3 25 | 87.1% | — | ||
| Q2 25 | 86.1% | 62.7% | ||
| Q1 25 | 90.3% | 67.9% | ||
| Q4 24 | 88.6% | 65.3% | ||
| Q3 24 | 88.8% | 63.2% |
| Q2 26 | 28.5% | — | ||
| Q1 26 | 17.9% | — | ||
| Q4 25 | 17.9% | 18.4% | ||
| Q3 25 | 9.7% | — | ||
| Q2 25 | 15.1% | -7.5% | ||
| Q1 25 | 29.2% | 12.2% | ||
| Q4 24 | 22.4% | 16.0% | ||
| Q3 24 | 15.2% | 13.8% |
| Q2 26 | 24.0% | — | ||
| Q1 26 | 15.4% | — | ||
| Q4 25 | 15.4% | 12.8% | ||
| Q3 25 | 16.1% | — | ||
| Q2 25 | 14.6% | -5.6% | ||
| Q1 25 | 24.8% | 7.1% | ||
| Q4 24 | 19.0% | 11.7% | ||
| Q3 24 | 19.2% | 11.6% |
| Q2 26 | $0.99 | — | ||
| Q1 26 | $0.55 | — | ||
| Q4 25 | $0.55 | $0.24 | ||
| Q3 25 | $0.50 | — | ||
| Q2 25 | $0.48 | $-0.11 | ||
| Q1 25 | $0.94 | $0.14 | ||
| Q4 24 | $0.70 | $0.22 | ||
| Q3 24 | $0.59 | $0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $594.7M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $2.6B | $2.0B |
| Total Assets | $3.2B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $594.7M | — | ||
| Q1 26 | $644.6M | — | ||
| Q4 25 | $644.6M | $172.9M | ||
| Q3 25 | $702.6M | — | ||
| Q2 25 | $699.3M | $162.2M | ||
| Q1 25 | $626.6M | $140.7M | ||
| Q4 24 | $520.8M | $177.5M | ||
| Q3 24 | $482.0M | $187.5M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M |
| Q2 26 | $2.6B | — | ||
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.6B | $2.0B | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.6B | $1.9B | ||
| Q1 25 | $2.6B | $2.0B | ||
| Q4 24 | $2.5B | $2.1B | ||
| Q3 24 | $2.5B | $2.1B |
| Q2 26 | $3.2B | — | ||
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | $2.5B | ||
| Q3 25 | $3.2B | — | ||
| Q2 25 | $3.2B | $2.6B | ||
| Q1 25 | $3.2B | $2.6B | ||
| Q4 24 | $3.2B | $2.7B | ||
| Q3 24 | $3.1B | $2.7B |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $147.3M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.55× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $147.3M | — | ||
| Q1 26 | $54.8M | — | ||
| Q4 25 | $54.8M | — | ||
| Q3 25 | $472.2M | — | ||
| Q2 25 | $67.7M | $98.2M | ||
| Q1 25 | $174.9M | $41.1M | ||
| Q4 24 | $106.8M | $84.3M | ||
| Q3 24 | $327.3M | $63.9M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $50.2M | — | ||
| Q3 25 | $435.9M | — | ||
| Q2 25 | $61.3M | $93.3M | ||
| Q1 25 | $168.0M | $31.0M | ||
| Q4 24 | $100.0M | $77.5M | ||
| Q3 24 | $297.2M | $54.7M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 14.5% | — | ||
| Q3 25 | 142.0% | — | ||
| Q2 25 | 19.4% | 29.4% | ||
| Q1 25 | 45.5% | 9.8% | ||
| Q4 24 | 28.0% | 26.1% | ||
| Q3 24 | 97.5% | 18.9% |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.3% | — | ||
| Q3 25 | 11.8% | — | ||
| Q2 25 | 2.0% | 1.5% | ||
| Q1 25 | 1.9% | 3.2% | ||
| Q4 24 | 1.9% | 2.3% | ||
| Q3 24 | 9.8% | 3.2% |
| Q2 26 | 1.55× | — | ||
| Q1 26 | 1.03× | — | ||
| Q4 25 | 1.03× | — | ||
| Q3 25 | 9.57× | — | ||
| Q2 25 | 1.47× | — | ||
| Q1 25 | 1.91× | 1.82× | ||
| Q4 24 | 1.57× | 2.42× | ||
| Q3 24 | 5.59× | 1.90× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DLB
| Licensing | $372.2M | 94% |
| Products and services | $23.4M | 6% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
